Drug Discovery World
Multiplexing Specificity and Species Cross Reactivity Assays in Biologics Discovery

Multiplexing Specificity and Species Cross Reactivity Assays in Biologics Discovery

Sponsored by intellicyt

Available to view for free on demand

Biologics are one of the fastest growing classes of drugs. Their beneficial, and often dramatic therapeutic effects are due to their high specificity and affinity to target antigens. During the biologics discovery the ability to evaluate antigen-antibody interactions via multiplexed binding assays at high throughput provides more information in the primary screening phase.

Identifying hits by simultaneous evaluation specificity and cross-reactivity builds confidence in potential hits and increases the likelihood that candidate molecules will successfully proceed through downstream steps in the discovery and development process.

This free webinar features two speakers who will both demonstrate how high throughput multiplexed assays enhanced productivity in their biologics discovery workflow.

You can view the webinar on demand by following the link below, you'll need to register to view.


View The Webinar


About the speakers

Firstly, Yana Wang, Ph.D., from Takeda Pharmaceuticals will highlight how they multiplex multiple cell lines of interest in one well to simultaneously quantitate on-target activity, cross-reactivity and non-specific activity along with measurement of antibody concentration using, the Intellicyt iQue Screener PLUS platform. This ability to measure multiple parameters coupled with the platform’s speed and increased accuracy provides gains in productivity and helps accelerate antibody discovery.

Secondly, Robert Ford, Ph.D., from Avacta Life Sciences will provide an overview of novel Anti-idiotpyic Affimer® reagents and their importance in the bioanalysis of therapeutic antibody drug candidates and demonstrate how these Affimer® reagents are identified using the Intellicyt iQue Screener platform by incorporating cross-reactivity profiling against similar antibody drug candidates into the primary screening phase of the discovery process.